Patents Assigned to INTEGRATIVE RESEARCH LABORATORIES
  • (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
    Patent number: 11078158
    Abstract: The disclosure provides a process for manufacturing thereof a salt of Formula IIb:
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 3, 2021
    Assignee: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
    Inventors: Clas Sonesson, Maija Buksa, Inese Reine
  • Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
    Patent number: 10875829
    Abstract: The disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I): (I) or an isotope labelled analog thereof, or a pharmaceutically acceptable salt thereof, wherein: each of R1, R2, R3, R6 and R7 represents H or F, R4 represents H or CH3 R5 represents H or C1-C4alkyl, wherein at least two of R1, R2, R3, R6 and R7 represent F, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 29, 2020
    Assignee: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
    Inventors: Clas Sonesson, Fredrik Pettersson
  • Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
    Patent number: 10287247
    Abstract: The present disclosure relates to certain novel compounds and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: May 14, 2019
    Assignee: Integrative Research Laboratories Sweden AB
    Inventors: Fredrik Pettersson, Clas Sonesson
  • Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
    Patent number: 10087142
    Abstract: The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 2, 2018
    Assignee: INTEGRATIVE RESEARCH LABORATORIES
    Inventors: Fredrik Pettersson, Clas Sonesson
  • Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
    Patent number: 9120728
    Abstract: The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 1, 2015
    Assignee: Integrative Research Laboratories Sweden AB
    Inventors: Clas Sonesson, Jonas Karlsson, Peder Svensson
  • NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION
    Publication number: 20150148426
    Abstract: The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 28, 2015
    Applicant: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
    Inventors: Clas SONESSON, Jonas KARLSSON, Peder SVENSSON
  • 3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
    Patent number: 9035073
    Abstract: The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: May 19, 2015
    Assignee: Integrative Research Laboratories Sweden AB
    Inventors: Clas Sonesson, Lars Swanson, Fredrik Pettersson
  • Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
    Patent number: 9006227
    Abstract: The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: April 14, 2015
    Assignee: Integrative Research Laboratories Sweden AB
    Inventors: Clas Sonesson, Jonas Karlsson, Peder Svensson
  • 3-PHENYL-3-METHOXY-PYRROLIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION
    Publication number: 20140135505
    Abstract: The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.
    Type: Application
    Filed: January 22, 2014
    Publication date: May 15, 2014
    Applicant: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB
    Inventors: Clas SONESSON, Lars SWANSON, Fredrik PETTERSSON
  • NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION
    Publication number: 20140128360
    Abstract: The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: April 17, 2012
    Publication date: May 8, 2014
    Applicant: Integrative Research Laboratories Swenden AB
    Inventors: Clas Sonesson, Jonas Karlsson, Peder Svensson
  • 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
    Patent number: 8673962
    Abstract: The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: March 18, 2014
    Assignee: Integrative Research Laboratories Sweden AB
    Inventors: Clas Sonesson, Lars Swanson, Fredrik Pettersson
  • 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
    Patent number: 8586572
    Abstract: The present invention relates to novel 3-phenyl-azetidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-azetidine derivatives of the invention and to the use of these compounds for therapeutic applications.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: November 19, 2013
    Assignee: Integrative Research Laboratories Sweden AB
    Inventors: Clas Sonesson, Lars Swanson, Fredrik Pettersson